- Trials with a EudraCT protocol (742)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (65)
742 result(s) found for: Agonist.
Displaying page 1 of 38.
| EudraCT Number: 2008-008722-73 | Sponsor Protocol Number: PPP/2008 | Start Date*: 2009-04-20 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA PISANA | |||||||||||||
| Full Title: ROLE OF PAROXETINE AS ADD-ON THERAPY TO GNRH AGONIST IN THE TREATMENT OF ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN | |||||||||||||
| Medical condition: Endometriosis-associated pelvic pain | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003645-16 | Sponsor Protocol Number: 2019_0012 | Start Date*: 2020-02-25 |
| Sponsor Name:Hopital Foch | ||
| Full Title: Benefit of the GnRH agonist before frozen embryo transfer in patients with endometriosis and / or adenomyosis: randomized prospective study | ||
| Medical condition: Frozen embryo transfer in patients with endometriosis and/or adenomyosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-000585-22 | Sponsor Protocol Number: FE 200486 CS27 | Start Date*: 2008-06-20 |
| Sponsor Name:Ferring Arzneimittel GmbH | ||
| Full Title: An Open-Label, Multi-Centre, Uncontrolled, Exploratory Study, Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment after PSA-Failure in GnRH Agonist Treated Patients w... | ||
| Medical condition: Prostate Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-002010-38 | Sponsor Protocol Number: SC3-90049-001 | Start Date*: 2005-11-21 |
| Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S.) | ||
| Full Title: Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson D... | ||
| Medical condition: Advanced Parkinson´s Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-001338-32 | Sponsor Protocol Number: NFPA12 | Start Date*: 2012-09-24 | |||||||||||
| Sponsor Name:St. Olavs Hospital Trondheim University Hospital | |||||||||||||
| Full Title: Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs) - a randomized controlled trial. The efficacy of cabergoline on tumour volume in previously untreated macroadenomas or resid... | |||||||||||||
| Medical condition: non-functioning pituitary adenomas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001403-33 | Sponsor Protocol Number: TCTLR-101 | Start Date*: 2023-06-06 | ||||||||||||||||||||||||||
| Sponsor Name:Ascendis Pharma Oncology Division A/S | ||||||||||||||||||||||||||||
| Full Title: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor... | ||||||||||||||||||||||||||||
| Medical condition: Locally advanced or metastatic solid tumor malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) HU (Prematurely Ended) NL (Trial now transitioned) PL (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2013-000821-30 | Sponsor Protocol Number: SAD13-ER1 | Start Date*: 2013-07-12 |
| Sponsor Name:Enrique Rey Díaz-Rubio | ||
| Full Title: CLINICAL RESPONSE TO 5HT4 RECEPTORS AGONIST (PRUCALOPRIDE): GASTROCOLIC REFLEX | ||
| Medical condition: chronic constipation | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-004460-31 | Sponsor Protocol Number: PRINT | Start Date*: 2007-02-21 | |||||||||||
| Sponsor Name:Guy's & St Thomas' NHS Foundation Trust | |||||||||||||
| Full Title: A randomised controlled trial comparing the gonadotrophin releasing hormone (GnRH) agonist long regimen versus the GnRH agonist short regimen versus the GnRH antagonist regimen in poor responders u... | |||||||||||||
| Medical condition: Poor ovarian response in women undergoing In vitro Fertilisation (IVF) treatment. | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000794-31 | Sponsor Protocol Number: October2011,version5 | Start Date*: 2011-06-15 | |||||||||||
| Sponsor Name:Dept. of Pharmacology | |||||||||||||
| Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes | |||||||||||||
| Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004213-16 | Sponsor Protocol Number: A-97-52014-181 | Start Date*: 2012-05-01 |
| Sponsor Name:Ipsen Ltd | ||
| Full Title: A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-... | ||
| Medical condition: locally advanced and metastatic prostrate cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-004096-19 | Sponsor Protocol Number: BALTI Prev 2007 | Start Date*: 2007-10-31 |
| Sponsor Name:Birmingham Heartlands Hospital | ||
| Full Title: Beta Agonist Lung injury Trial - Prevention Study | ||
| Medical condition: This programme of research will examine the role of beta-2 agonist as specific pharmacotherapy to reduce the incidence of Acute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) in pat... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003001-94 | Sponsor Protocol Number: MSGLP | Start Date*: 2019-11-06 | |||||||||||
| Sponsor Name:Lekárska fakulta UK Bratislava | |||||||||||||
| Full Title: Use of GLP-1 analogs in the treatment of multiple sclerosis | |||||||||||||
| Medical condition: Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurode... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-004709-53 | Sponsor Protocol Number: 911 | Start Date*: 2005-12-05 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme OÜ | |||||||||||||
| Full Title: A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patient... | |||||||||||||
| Medical condition: Asthma | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Completed) ES (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-021403-24 | Sponsor Protocol Number: 001 | Start Date*: 2010-11-10 | |||||||||||
| Sponsor Name:North Lincolnshire and Goole NHS Foundation Trust | |||||||||||||
| Full Title: A Prospective Pilot Study to Investigate the Effectiveness of Quinagolide in the Improvement of Psychological Symptoms Associated with Hyperprolactinaemia. | |||||||||||||
| Medical condition: Hyperprolactinaemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-005631-29 | Sponsor Protocol Number: 24420221 | Start Date*: 2008-06-18 | |||||||||||
| Sponsor Name:Center for Spiseforstyrrelse, Endokrinologisk Afdeling M, Odense Universitetshospital | |||||||||||||
| Full Title: Cannabinoid CB1 receptor agonist treatment in severe chronic anorexia nervosa | |||||||||||||
| Medical condition: severe chronic Anorexia Nervosa | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001191-34 | Sponsor Protocol Number: ASND0029 | Start Date*: 2023-07-14 | |||||||||||
| Sponsor Name:Ascendis Pharma Oncology Division A/S | |||||||||||||
| Full Title: IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, Standard of... | |||||||||||||
| Medical condition: locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-s... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003986-11 | Sponsor Protocol Number: 1401-MAD-004-IO | Start Date*: 2016-10-22 |
| Sponsor Name:IVI Madrid | ||
| Full Title: Prospective, double-blinded, randomized clinical trial to evaluate the potential benefitial effect of resveratrol for preventing the ovarian hyperstimulation syndrome. | ||
| Medical condition: Resveratrol may prevent the incidence of ovarian hyperstimulation syndrome by reducing the expression of VEGF and estradiol, improving the haemoconcentration and ascitis Re | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-003861-34 | Sponsor Protocol Number: 0/2004 | Start Date*: 2005-06-08 |
| Sponsor Name:Department of Nuclear Medicine | ||
| Full Title: Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects | ||
| Medical condition: There is an association between insulin resistance and endothelial dysfunction which is thought to be a critical factor in the development of vascular disease and thus an important factor in the de... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-003871-19 | Sponsor Protocol Number: srhths01 | Start Date*: 2006-09-19 |
| Sponsor Name:Salford Royal Hospital | ||
| Full Title: A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease | ||
| Medical condition: Secondary hyperparathyroidism in renal failure | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-004245-16 | Sponsor Protocol Number: NL67646.068.18 | Start Date*: 2019-04-16 |
| Sponsor Name:Maastricht University | ||
| Full Title: Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humans | ||
| Medical condition: Type 2 diabetes | ||
| Disease: | ||
| Population Age: Adults | Gender: Male | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.